by Shuling Zhou,
Ting Liu, Xiaying Kuang, Tiantian Zhen, Huijuan Shi, Ying Lin, Nan Shao
The Breast: Published: December 13, 2022
Novel anti-HER2 antibody-drug conjugates trastuzumab
deruxtecan (DS-8201a) showed its effect in previously-treated HER2-low
metastatic breast cancer, suggesting a promising future in HER2-low breast
cancer. We retrospectively reviewed the clinicopathological data of 325
patients with stage I–III HER2 negative breast cancer who received neoadjuvant
chemotherapy in the First Affiliated Hospital of Sun Yat-sen University from
January 2016 to June 2021. In general, 91 patients (28.0%) were HER2-zero, and
234 patients (72.0%) were HER2-low. The pathological complete response (pCR)
rate of the entire cohort was 17.3%. The pCR rate was 16.7% in HER2-low group,
and 18.9% in HER2-zero group, showing no significant difference. Patients with
HER2-low tumors had significantly longer overall survival (OS) than patients
with HER2-zero tumors. ER status was the affecting factor of OS in HER2-low
patients in both univariate and multivariate analysis. In conclusion, evidence
for HER2-low BC as a distinct entity is insufficient, and more efforts are
needed to standardize the scoring of HER2-low breast cancer.
